Long-term in vivo monitoring of transplanted mesenchymal stromal cells in colitis mice with magnetic particle imaging.

阅读:8
作者:Shao Tuo, Gu Zelin, Liu Yuzhu, Wang Xiaoyi, Tang Chao, Chen Nannan, Wang Mengqi, Liu Xueqin, Song Huanhuan, Chen Siye, Li Weihua, Hui Hui, Jia Xiaohua, Mao Hui, Chung Raymond T, Liang Steven, Xiong Sidong, Tian Jie
BACKGROUND: The successful development of mesenchymal stromal cells (MSCs)-based therapeutic strategies in inflammatory bowel disease (IBD) hinges on the ability to assess the influence of the administration route, while also tracking the cells' in vivo location, distribution, and long-term viability. Moreover, understanding the biological fate of these cells-particularly their activation, differentiation, and interaction within the host environment-is crucial to optimising their therapeutic potential. METHODS: This study explores the use of magnetic particle imaging (MPI) with superparamagnetic iron oxide nanoparticles (SPIONs) to track MSCs in colitis mice. SPION-labelled MSCs were administered through intravenous (IV), intraperitoneal (IP), and intrarectal (IR) routes. MPI was employed to track MSCs. FINDINGS: MPI provided dynamic tracking of MSC distribution, viability, and homing, revealing that IP injections led to more targeted and sustained delivery to inflamed colon tissues, with higher cell survival and efficacy in modulating inflammation. Other administration routes also demonstrated specific distribution patterns, but with shorter retention times. The prolonged survival of MSCs following IP injection may be attributed to the immune environment in the peritoneal cavity, which significantly impacts MSCs, influencing their survival and migration. Further analyses showed that MSCs exposed to inflammatory peritoneal fluid exhibited enhanced homing capabilities, and IFN-γ pretreatment significantly improved MSC retention in the inflamed colon, as detected by MPI/CT imaging. INTERPRETATION: Our findings, observed through MPI, highlight the potential of IP injection as a preferred method for MSC-based therapies, offering strategies to improve treatment outcomes specifically in IBD and potentially in other inflammatory conditions. FUNDING: The National Natural Science Foundation of China (62027901, 82372144), the Natural Science Foundation of Jiangsu Province (BK20230491), a Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

特别声明

1、本文转载旨在传播信息,不代表本网站观点,亦不对其内容的真实性承担责任。

2、其他媒体、网站或个人若从本网站转载使用,必须保留本网站注明的“来源”,并自行承担包括版权在内的相关法律责任。

3、如作者不希望本文被转载,或需洽谈转载稿费等事宜,请及时与本网站联系。

4、此外,如需投稿,也可通过邮箱info@biocloudy.com与我们取得联系。